Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — H1 2023/24 Earnings Presentation
11 slides from Coloplast A/s Class B's earnings presentation, May 7, 2024
Slide 1: Making life easier
Conference call presentation H1 2023/24 Making life Tanja - Continence Care user easier Strive25: Sustainable Growth Leadership Ostomy Care | Continence Care | Advanced Wound Care | Interventional Urology | Voice and Respiratory Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Q2 2023/24 financial result in line with guidance
NEW IMAGE Q2 2023/24 financial result in line with guidance Otto: add picture with Peristeen Light Update picture Organic Reported ROIC growth EBIT margin 8% 27% * * 15% ** *before special items **after tax and before special items 3 Heylo
Slide 4: Clinical evidence qualification in recent draft LCD policy is a positive development
Clinical evidence qualification in recent draft LCD* policy is a positive development; Kerecis well positioned to get back on the covered list Draft LCD policy from 25 April introduces two coverage qualifications and Latest relevant clinical data has been omitted from assessment and will be relates
Slide 5: Strategic highlights from Strive25 – Sustainable growth leadership
Strategic highlights from Strive25 – Sustainable growth leadership Growth Innovation Atos Medical Luja , a new intermittent catheter with a Micro-hole Zone Technology • Strong H1 2023/24 performance with 10% growth; both the laryngectomy and tracheostomy • Launch of Luja for men in key markets concl
Slide 6: Solid H1 with 8% organic growth, driven by Chronic Care
Solid H1 with 8% organic growth, driven by Chronic Care H1 2023/24 revenue by business area H1 2023/24 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm growth Ostomy Care 4,663 7% 35%
Slide 7: H1 reported revenue grew 8% with Kerecis contribution and currency impact
H1 reported revenue grew 8% with ~4%-points contribution from the Kerecis acquisition and ~3%-points negative impact from currencies H1 2023/24 Revenue development (mDKK) H1 2023/24 highlights • Reported revenue increased by DKK 1,026 million or 8% vs. last year. • Organic growth was 8% or DKK 915 m
Slide 8: Reported EBIT margin of 27% in H1, impacted by currency and Kerecis dilution
Reported EBIT margin of 27%1 in H1, negatively impacted by currency headwind and ~100 basis points dilution from Kerecis, as expected H1 2023/24 EBIT margin development before special items (%) H1 2023/24 highlights • Gross margin was 68%, compared to 67% last year • Positive impact from: decrease i
Slide 9: Adj. FCF of DKK 1,174 million in H1
Adj. FCF of DKK 1,174 million in H1. Operating cash flow impacted by the extraordinary tax payment related to the Atos Medical IP transfer FCF development1 H1 2023/24 highlights 98 • Free cash flow for H1 2023/24 was an outflow of DKK 1,326 million vs an 90 93 87 inflow of DKK 795 million last year,
Slide 10: Unchanged organic growth guidance of around 8% and EBIT margin guidance of 27-28%
Unchanged organic growth guidance of around 8% and EBIT margin* guidance of 27-28%; reported growth adjusted to 10-11% due to FX Organic revenue growth Around 8% Reported revenue growth in DKK 10-11% Reported EBIT margin* 27-28% Effective tax rate Around 22% Capital expenditures Around 1.4 bn DKK *b
Slide 11: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding